FDA Accepts Supplemental NDA for Brilinta (Ticagrelor) by AstraZeneca
The FDA has accepted a supplemental NDA for Brilinta (ticagrelor) submitted by AstraZeneca.
Asset / Drug
Drug and asset intelligence for Brilinta with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 13, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.